New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT00045201
First seen Oct 01, 2025 · Last updated May 07, 2026 · Updated 32 times
Summary
This early-phase trial tests the safety and best dose of combining two drugs, erlotinib and irinotecan, in 60 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth. Participants must have tumors that overexpress a protein called EGFR and be willing to provide blood and tissue samples.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.